Tumor-infiltrating NKG2A+CD8+ T cells are the predominant lymphocyte subset in lung cancer, and the expression of NKG2A on tumor-infiltrating CD8+ T cells also regulated by TCR, thus NKG2A+CD8+ T cells may offer an efficient solution for immunotherapy for lung cancer (119). This evidence concerns the gene CD8A and lung carcinoma.